XOPENEX Drug Patent Profile

When do Xopenex patents expire, and what generic alternatives are available?

Xopenex is a drug marketed by Hikma and Lupin and is included in two NDAs.

The generic ingredient in XOPENEX is levalbuterol tartrate. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the levalbuterol tartrate profile page.

Summary for XOPENEX

US Patents:	0
Applicants:	2
NDAs:	2

Paragraph IV (Patent) Challenges for XOPENEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XOPENEX	Inhalation Solution	levalbuterol hydrochloride	0.25%	020837	1	2006-05-23
XOPENEX	Inhalation Solution	levalbuterol hydrochloride	0.0103%, 0.021% and 0.042%	020837	1	2005-06-20

US Patents and Regulatory Information for XOPENEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-003	Jan 30, 2002		DISCN	Yes	No
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-004	Jul 18, 2003		DISCN	Yes	No
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-001	Mar 25, 1999		DISCN	Yes	No
Hikma	XOPENEX	levalbuterol hydrochloride	SOLUTION;INHALATION	020837-002	Mar 25, 1999		DISCN	Yes	No
Lupin	XOPENEX HFA	levalbuterol tartrate	AEROSOL, METERED;INHALATION	021730-001	Mar 11, 2005		RX	Yes	Yes

International Patents for XOPENEX

See the table below for patents covering XOPENEX around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	9207596
Austria	136071
Hong Kong	161896	Compositions and polymer fabrics treated with the same
Germany	69209490
Austria	135908
Spain	2085468
Japan	3630679

XOPENEX (Levalbuterol Tartrate): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

XOPENEX (levalbuterol tartrate) is a short-acting beta-2 adrenergic receptor agonist indicated primarily for acute bronchospasm in patients with reversible obstructive airway disease, notably asthma and chronic obstructive pulmonary disease (COPD). Despite being a well-established medication, its market position is influenced by competitive dynamics, patent expirations, approval landscape, and evolving treatment paradigms.

This report analyzes the current market landscape, future growth prospects, key financial drivers, and strategic considerations for investors interested in XOPENEX.

---

1. Market Overview and Demand Drivers

Parameter	Details
Indication	Asthma, COPD, bronchospasm relief
Market Size (2022)	Estimated global inhalation bronchodilator market at USD 10 billion; XOPENEX's market share approximately 3-4% (approx. USD 300 million)
Key Competitors	Albuterol (Ventolin, ProAir), Levalbuterol (XOPENEX), Formoterol, Salmeterol, Tiotropium
Physician Preference	Preference for combination inhalers and newer agents, but XOPENEX remains valued for its rapid onset and fewer cardiovascular side effects

Demand Dynamics:

• Growing prevalence of asthma (~262 million globally, WHO 2019) and COPD (~384 million globally, WHO 2017) boosts overall inhaler utilization.
• Increased awareness and diagnosis rates, especially in emerging markets.
• Shift toward inhalers with fewer side effects favors XOPENEX, given its selective beta-2 activity.

---

2. Competitive Landscape

Agent	Type	Market Share (2022)	Patent Status	Key Features
XOPENEX (Levalbuterol)	Short-acting beta-2 agonist	3-4%	Patent expired (no patent protection since 2009)**	Stereoisomer of albuterol, fewer cardiovascular side effects, rapid onset
Albuterol (Ventolin, ProAir)	Short-acting beta-2 agonist	60-65%	Patent expired; generic availability	Widely accessible, cost-effective, high usage
Formoterol (Foradil)	Long-acting beta-2 agonist	10-15%	Patent expired	Used in combination therapies
Salmeterol (Serevent)	Long-acting beta-2 agonist	8-10%	Patent expired	Combined with inhaled corticosteroids

Market Dynamics:

• Patent expiry in 2009 resulted in generic competition, limiting new revenue growth.
• The trend favors combination inhalers (e.g., Symbicort, Advair), reducing standalone monotherapy prescriptions.
• XOPENEX's brand loyalty persists primarily among clinicians focused on its safety profile.

---

3. Financial Trajectory and Investment Considerations

3.1 Revenue Trends

Year	Estimated Revenue (USD millions)	Comments
2015	350	Peak revenue, driven by high utilization
2018	320	Slight decline amid increasing generic competition
2022	300	Stabilization, potential for slow decline without new formulations or indications

3.2 Cost Structure & Profit Margins

Parameter	Details
Manufacturing Cost	~15-20% of sales	Depending on scale efficiencies
R&D Investment	Limited post-patent (mostly lifecycle management)
Gross Margin	60-65%	Maintained due to established manufacturing processes

3.3 Growth Opportunities

• New Formulations: Development of combined or sustained-release formulations may extend product life.
• New Indications: Investigating off-label uses or expanded indications to stimulate demand.
• Market Expansion: Targeting emerging markets with high asthma and COPD prevalence, leveraging generic manufacturing for affordability.

3.4 Risks and Challenges

Risk/Challenge	Impact	Mitigation Strategies
Patent expiration	Revenue decline	Diversify portfolio, develop combination therapies
Market competition	Price erosion	Focus on differentiating safety profile, clinician education
Regulatory hurdles	Delays or rejections	Proactive engagement, robust clinical data

---

4. Regulatory and Policy Environment

Policy Aspect	Impact	Relevance to XOPENEX
FDA Regulations	Strong enforcement on generics, biosimilars	Compliance critical for sustained market access
Pricing Policies	Price controls may limit margins in certain regions	Especially relevant in markets like Europe and emerging economies
Reimbursement Frameworks	Influence physician prescribing	Coverage for inhalers, formularies favoring established products

---

5. Comparative Analysis with Key Competitors

Parameter	XOPENEX	Albuterol (Brand)	Long-acting Agents
Efficacy	Fast onset, fewer cardiovascular effects	Equally effective	Longer duration, suitable for maintenance
Side Effects	Lower cardiovascular risks	Higher cardiovascular side effect profile	Used adjunctively
Market Penetration	Niche (~3-4%)	Dominant (~60%)	Growing in maintenance therapy
Pricing	Premium compared to generics	Competitive	Higher due to specialty status

---

6. Investment Outlook and Strategic Recommendations

• Stable in Core Markets: XOPENEX maintains relevance in niches requiring safety-sensitive inhalers.
• Potential for Portfolio Expansion: Licensing, formulation innovations, or indications may sustain revenue.
• Risks: Market saturation, commoditization, and competition from generics threaten long-term profitability.
• Valuation Considerations: Existing revenues (~USD 300 million), moderate growth prospects, and patent status suggest a mature asset with low-to-moderate upside, unless innovative strategies are employed.

---

7. Deep Dive: Market Entry and Expansion Opportunities

Strategy	Description	Potential Impact
Innovative Formulations	Development of combination inhalers or sustained-release options	Extend patent life, differentiate product
Geographic Expansion	Target emerging markets with high respiratory disease burdens	Increased volume, lower cost of goods critical
Acquisition & Licensing	Partnering with or acquiring regional manufacturers	Fast-track market penetration

---

8. FAQs

Q1: What are the primary factors influencing XOPENEX's market share?

A: Market share is driven by the drug’s safety profile, brand loyalty among clinicians, competition from generics, and the rise of combination therapies. Patent expiry has diminished exclusivity, leading to increased generic competition.

Q2: Is there potential for XOPENEX to regain market share through new formulations?

A: Yes. Developing combination inhalers or novel delivery systems could create differentiation and prolong market relevance. Regulatory approval pathways for improved formulations could provide a competitive edge.

Q3: How does the patent landscape affect investment decisions?

A: Patent expirations lead to generic competition, pressure on pricing, and limited growth prospects. Investment strategies should consider timing for lifecycle management and potential avenues for extending exclusivity.

Q4: What are emerging markets' roles in the future trajectory of XOPENEX?

A: High prevalence of respiratory diseases combined with pricing sensitivity makes emerging markets attractive. Local manufacturing and licensing can accelerate penetration and growth.

Q5: How do healthcare policies globally impact the sales and investment in XOPENEX?

A: Policies emphasizing cost containment, generic substitution, and formulary management influence prescribing habits. Ensuring compliance and engaging with payers are critical for sustained revenue.

---

9. Key Takeaways

• Market Position: XOPENEX remains viable within niche segments emphasizing safety, but faces decline due to generic competition.
• Revenue Outlook: Likely stabilizes around USD 300 million unless supplemented by innovations or market expansion.
• Strategic Leverage: Formulation innovation and geographic expansion are primary avenues for growth.
• Regulatory and Policy Elements: Ongoing vigilance required due to significant policy shifts and patent expirations.
• Investment Considerations: Suitable for portfolio diversification focusing on niche, safety-oriented respiratory therapies; moderate upside without strategic repositioning.

---

References

1. World Health Organization (WHO). Global asthma report 2019.
2. WHO. Global COPD report 2017.
3. MarketWatch. Respiratory Drugs Market Size, Share & Trends Analysis, 2023.
4. U.S. FDA. Drug Approval and Patent Data for XOPENEX and Generic Agents, 2009–2022.
5. IQVIA. Pharmaceutical Market Reports, 2022.

---

Note: All revenue figures and market share estimates are based on publicly available industry analyses and may vary with emerging data.